These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 36591300)
21. Clinical Profile, Dosing, and Quality-of-Life Outcomes in Primary Immune Deficiency Patients Treated at Home with Immunoglobulin G: Data from the IDEaL Patient Registry. Kearns S; Kristofek L; Bolgar W; Seidu L; Kile S J Manag Care Spec Pharm; 2017 Apr; 23(4):400-406. PubMed ID: 28345437 [TBL] [Abstract][Full Text] [Related]
23. Home-based subcutaneous immunoglobulin therapy vs hospital-based intravenous immunoglobulin therapy: A prospective economic analysis. Fu LW; Song C; Isaranuwatchai W; Betschel S Ann Allergy Asthma Immunol; 2018 Feb; 120(2):195-199. PubMed ID: 29413344 [TBL] [Abstract][Full Text] [Related]
24. Switching Patients to Home-Based Subcutaneous Immunoglobulin: an Economic Evaluation of an Interprofessional Drug Therapy Management Program. Perraudin C; Bourdin A; Spertini F; Berger J; Bugnon O J Clin Immunol; 2016 Jul; 36(5):502-10. PubMed ID: 27139500 [TBL] [Abstract][Full Text] [Related]
25. Primary immunodeficiency disease: a cost-utility analysis comparing intravenous vs subcutaneous immunoglobulin replacement therapy in Australia. Windegger TM; Nghiem S; Nguyen KH; Fung YL; Scuffham PA Blood Transfus; 2020 Mar; 18(2):96-105. PubMed ID: 32271703 [TBL] [Abstract][Full Text] [Related]
26. Long-Term Experience of Subcutaneous Immunoglobulin Therapy in Pediatric Primary Immunodeficient Patients with Low and Normal Body Weight. Gul Y; Kapakli H; Guner SN; Alan HB; Hazar E; Keles S; Reisli I J Clin Immunol; 2022 Jan; 42(1):64-71. PubMed ID: 34617265 [TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases. Kanegane H; Imai K; Yamada M; Takada H; Ariga T; Bexon M; Rojavin M; Hu W; Kobayashi M; Lawo JP; Nonoyama S; Hara T; Miyawaki T J Clin Immunol; 2014 Feb; 34(2):204-11. PubMed ID: 24504846 [TBL] [Abstract][Full Text] [Related]
29. Overview of subcutaneous immunoglobulin 16.5% in primary and secondary immunodeficiency diseases. Kobayashi RH; Litzman J; Rizvi S; Kreuwel H; Hoeller S; Gupta S Immunotherapy; 2022 Mar; 14(4):259-270. PubMed ID: 34986666 [TBL] [Abstract][Full Text] [Related]
30. Subcutaneous immunoglobulin (16 or 20%) therapy in obese patients with primary immunodeficiency: a retrospective analysis of administration by infusion pump or subcutaneous rapid push. Shapiro R Clin Exp Immunol; 2013 Aug; 173(2):365-71. PubMed ID: 23607310 [TBL] [Abstract][Full Text] [Related]
32. [Replacement therapy with subcutaneous immunoglobulin in primary immunodeficiency in children]. Pac M Pol Merkur Lekarski; 2011 Jun; 30(180):413-6. PubMed ID: 21751550 [TBL] [Abstract][Full Text] [Related]
33. Efficacy and Tolerability of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Neurologic Diseases. Chen Y; Wang C; Xu F; Ming F; Zhang H Clin Ther; 2019 Oct; 41(10):2112-2136. PubMed ID: 31445679 [TBL] [Abstract][Full Text] [Related]
34. Intravenous and subcutaneous immunoglobulin G replacement therapy. Bonilla FA Allergy Asthma Proc; 2016 Nov; 37(6):426-431. PubMed ID: 27931296 [TBL] [Abstract][Full Text] [Related]
35. Population pharmacokinetics of immunoglobulin G after intravenous, subcutaneous, or hyaluronidase-facilitated subcutaneous administration in immunoglobulin-naive patients with primary immunodeficiencies. Li Z; Follman K; Freshwater E; Engler F; Yel L Int Immunopharmacol; 2024 Feb; 128():111447. PubMed ID: 38185032 [TBL] [Abstract][Full Text] [Related]
36. A Comparative Study of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Adult Patients with Primary Immunodeficiency Diseases: A Systematic Review and Meta-Analysis. Shabaninejad H; Asgharzadeh A; Rezaei N; Rezapoor A Expert Rev Clin Immunol; 2016; 12(5):595-602. PubMed ID: 26902306 [TBL] [Abstract][Full Text] [Related]
37. 20% subcutaneous immunoglobulin for patients with primary immunodeficiency diseases: A systematic review. Song J; Zhang L; Li Y; Quan S; Liang Y; Zeng L; Liu Y Int Immunopharmacol; 2015 Apr; 25(2):457-64. PubMed ID: 25633961 [TBL] [Abstract][Full Text] [Related]
38. Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency. Hoffmann F; Grimbacher B; Thiel J; Peter HH; Belohradsky BH; Eur J Med Res; 2010 Jun; 15(6):238-45. PubMed ID: 20696632 [TBL] [Abstract][Full Text] [Related]
39. Subcutaneous Immunoglobulin Therapy for Hypogammaglobulinemia Secondary to Malignancy or Related Drug Therapy. Windegger TM; Lambooy CA; Hollis L; Morwood K; Weston H; Fung YL Transfus Med Rev; 2017 Jan; 31(1):45-50. PubMed ID: 27450021 [TBL] [Abstract][Full Text] [Related]